Depression is common, costly, debilitating, and associated with increased risk of suicide. It is
one of the leading global public health problems. Although existing available …

Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Background In treatment-resistant depression, commonly defined as a lack of response to
two or more consecutive treatments during the current depressive episode, the percentage …

Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The
acute efficacy of ketamine in TRD has been demonstrated in replicated randomised …

Ketamine has rapid yet often transient antidepressant effects in patients with treatment-
resistant depression. Different strategies have been proposed to prolong these effects …

Depression is a well-known serious mental illness, and the onset of treatment using
traditional antidepressants is frequently delayed by several weeks. Moreover, numerous …

Background Elderly patients with major depression have a poorer prognosis, are less
responsive to treatment, and show greater functional decline compared with younger …

The efficacy of standard antidepressants is limited for many patients with mood disorders
such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent …

Patients with treatment-resistant depression (TRD) have higher rates of relapse and
pronounced decreases in daily functioning and health-related quality of life compared to …